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A B S T R A C T
Background
Symptomatic peripheral arterial disease may be treated by a number of options including exercise therapy, angioplasty, stenting and
bypass surgery. Atherectomy is an alternative technique where atheroma is excised by a rotating cutting blade.
Objectives
The objective of this review was to analyse randomised controlled trials comparing atherectomy against any established treatment for
peripheral arterial disease in order to evaluate the effectiveness of atherectomy.
Search methods
The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searchedNovember
2013) and CENTRAL (2013, Issue 10). Trials databases were searched for details of ongoing or unpublished studies.
Selection criteria
Randomised controlled trials (RCTs) comparing atherectomy and other established treatments were selected for inclusion. All partici-
pants had symptomatic peripheral arterial disease with either claudication or critical limb ischaemia and evidence of lower limb arterial
disease.
Data collection and analysis
Two review authors (GA and CT) screened studies for inclusion, extracted data and assessed the quality of the trials. Any disagreements
were resolved through discussion.
Main results
Four trials were included with a total of 220 participants (118 treated with atherectomy, 102 treated with balloon angioplasty) and 259
treated vessels (129 treated with atherectomy, 130 treated with balloon angioplasty). All studies compared atherectomy with angioplasty.
No study was properly powered or assessors blinded to the procedures and there was a high risk of selection, attrition, detection and
reporting biases.
The estimated risk of success was similar between the treatment modalities although the confidence interval (CI) was compatible with
small benefits of either treatment for the initial procedural success rate (Mantel-Haenszel risk ratio (RR) 0.92, 95% CI 0.44 to 1.91, P =
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0.82), patency at six months (Mantel-Haenszel RR 0.92, 95% CI 0.51 to 1.66, P = 0.79) and patency at 12 months (Mantel-Haenszel
RR 1.17, 95% CI 0.72 to 1.90, P = 0.53) following the procedure. The reduction in all-cause mortality with atherectomy was most
likely due to an unexpectedly high mortality in the balloon angioplasty group in one of the two trials that reported mortality (Mantel-
Haenszel RR 0.24, 95% CI 0.06 to 0.91, P = 0.04). Cardiovascular events were not reported in any study. There was a reduction in
the rate of bailout stenting following atherectomy (Mantel-Haenszel RR 0.45, 95% CI 0.24 to 0.84, P = 0.01), and balloon inflation
pressures were lower following atherectomy (mean difference -2.73 mmHg, 95% CI -3.48 to -1.98, P < 0.00001). Complications
such as embolisation and vessel dissection were reported in two trials indicating more embolisations in the atherectomy group and
more vessel dissections in the angioplasty group, but the data could not be pooled. From the limited data available, there was no clear
evidence of different rates of adverse events between the atherectomy and balloon angioplasty groups for target vessel revascularisation
and above-knee amputation. Quality of life and clinical and symptomatic outcomes such as walking distance or symptom relief were
not reported in the studies.
Authors’ conclusions
This review has identified poor quality evidence to support atherectomy as an alternative to balloon angioplasty in maintaining primary
patency at any time interval. There was no evidence for superiority of atherectomy over angioplasty on any outcome, and distal
embolisation was not reported in all trials of atherectomy. Properly powered trials are recommended.
P L A I N L A N G U A G E S U M M A R Y
Atherectomy for peripheral arterial disease
A person with diseased arteries in the legs can experience pain on walking (also known as intermittent claudication), pain at rest
(especially at night), or ulcers due to poor blood flow. Established treatments include surgery, where a bypass is inserted to carry blood
from an artery above the diseased (blocked or narrowed) section to below the diseased section, and balloon angioplasty, where a deflated
balloon is inserted into the vessel and then blown up to stretch the artery thus opening up the narrow or blocked section. Stents may be
inserted during angioplasty. In addition to these two established treatments, a less commonly used technique is to core out the artery,
cutting or grinding away the disease which is causing the vessel to narrow or block. This is known as atherectomy.
In this review, we compared atherectomy to the more established treatments such as balloon angioplasty and bypass surgery. We
identified four studies with a total of 220 participants. All studies compared atherectomy with balloon angioplasty. The studies were of
low quality as there was no blinding of the procedures, the studies were not properly powered to show an effect, not all study outcomes
were reported and a large number of the initial study populations did not complete the studies.
Although the results of the meta-analyses were imprecise, the average effect of the two treatments was similar in terms of initial
success and unobstructed arteries (patency) at six months or 12 months following the procedure. There was a lower risk of death with
atherectomy, most likely due to an unexpectedly high number of deaths in the balloon angioplasty group in one of the two trials
reporting deaths. Cardiovascular events were not reported in any of the included studies. There was a reduction in the rate of emergency
stenting procedures following atherectomy, and balloon inflation pressures were lower following atherectomy. Complications such as
formation of clots (embolisation) and tears along the vessels (vessel dissection) were reported in two trials indicating more embolisations
in the atherectomy group and more vessel dissections in the angioplasty group but the data could not be combined. The limited data
available indicated that there was no clear evidence of a difference between the atherectomy and balloon angioplasty groups for adverse
events such as the need for re-intervention due to obstruction of the treated vessel and above-knee amputation. Quality of life and
clinical and symptomatic outcomes such as walking distance or symptom relief were not reported in the studies.
We showed that the limited evidence available does not support a significant advantage of atherectomy over conventional balloon
angioplasty.
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B A C K G R O U N D
Description of the condition
Symptomatic peripheral arterial disease may be treated by a num-
ber of options including exercise therapy, angioplasty, stenting
and bypass surgery (Fowkes 1998; Fowkes 2008; Watson 2008).
Atherectomy is a competing technique where atheroma is excised
by a rotating cutting blade (Garcia 2009). Due to the risk of vessel
perforation, atherectomy tends to be performed only in the su-
perficial femoral and popliteal arteries, though it may be used in
infrapopliteal vessels. While established treatments have a strong
evidence base and guidelines for their use (TASC II 2007), the
outcomes for atherectomy are less well understood. Atherectomy
has suffered from a relative paucity of published data, which led
the National Institute for Health and Clinical Excellence (NICE)
in the United Kingdom to publish guidelines in early 2011 sug-
gesting that it should only be used within the context of clinical
trials (NICE 2011).
Description of the intervention
Atherectomy is an endovascular procedure for revascularisation
where pieces of atherosclerotic plaque are removed in order to
increase the luminal diameter of the vessel (Schwarzwalder 2010).
The procedure is normally performed percutaneously through a
7-French (F) or 8-F sheath unless vessel access is difficult, in which
case an arterial cut-down is required. The mechanism used to
remove pieces of plaque can involve a variety of techniques but
usually involves some kind of rotating cutting blade, often together
with a chamber for storing the cut pieces.
Why it is important to do this review
A true systematic review andmeta-analysis of published trials com-
paring atherectomy to more established treatments has never been
performed. Therefore, the aim was to perform a meta-analysis
of randomised trials comparing atherectomy with any established
treatment for peripheral arterial disease in order to evaluate the
effectiveness of atherectomy.
O B J E C T I V E S
The objective of this review was to analyse randomised controlled
trials comparing atherectomy against any established treatment for
peripheral arterial disease in order to evaluate the effectiveness of
atherectomy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) comparing atherectomy
with other established treatments were selected for inclusion.
Types of participants
All participants had symptomatic peripheral arterial disease with
either claudication or critical limb ischaemia and evidence of lower
limb arterial disease. Arterial disease in any peripheral territory
was considered.
Studies with participants who had previously had bypass, percuta-
neous transluminal angioplasty (PTA) or stents in the target lesion
were excluded as the treatments might affect the primary patency
rates.
Types of interventions
RCTs comparing atherectomy against any established treatment
for peripheral arterial disease in order to evaluate the effectiveness
of atherectomy were considered. The following trial comparisons
were identified: atherectomy versus balloon angioplasty ± stenting;
atherectomy plus adjunctive balloon angioplasty versus balloon
angioplasty; and atherectomy versus surgical bypass procedures.
Types of outcome measures
Primary outcomes
1. Primary vessel patency as assessed by ankle brachial index
(ABI), arterial doppler ultrasound or angiography at six months
and one year, and as data available in the studies
2. All-cause mortality at six months and one year, and as data
available in the studies
3. Fatal and non-fatal cardiovascular events at six months and
one year, and as data available in the studies
Secondary outcomes
1. Immediate procedural and angiographic outcomes
2. Target vessel revascularisation rates
3. Complication rates including thrombus, embolus,
perforation and aneurysm
4. Morbidity assessment including (i) tissue healing, (ii)
avoidance of any amputation and (iii) performance of less
extensive amputation
5. Quality of life outcomes as measured in the included studies
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6. Clinical and symptomatic outcomes e.g. improved walking
distance, symptom relief
Search methods for identification of studies
There was no language restriction.
Electronic searches
The Cochrane Peripheral Vascular Diseases Group Trials Search
Co-ordinator (TSC) searched the Specialised Register (last
searched November 2013) and the Cochrane Central Register
of Controlled Trials (CENTRAL) (2013, Issue 10), part of The
Cochrane Library (www.thecochranelibrary.com). See Appendix
1 for details of the search strategy used to search CENTRAL.
The Specialised Register is maintained by the TSC and is con-
structed from weekly electronic searches of MEDLINE, EM-
BASE, CINAHL and AMED, and through handsearching rele-
vant journals. The full list of the databases, journals and confer-
ence proceedings which have been searched, as well as the search
strategies used, are described in the Specialised Register section of
the Cochrane Peripheral Vascular Diseases Group module in The
Cochrane Library (www.thecochranelibrary.com).
The following trial databaseswere searchedby theTSC (November
2013) for details of ongoing and unpublished studies using the
term atherectomy:
• World Health Organization International Clinical Trials
Registry Platform (http://apps.who.int/trialsearch/);
• ClinicalTrials.gov (http://clinicaltrials.gov/);
• Current Controlled Trials (http://www.controlled-
trials.com/);
• Nederlands Trials Register (http://www.trialregister.nl/
trialreg/admin/rctsearch.asp).
Searching other resources
Reference lists of relevant articles resulting from this search were
searched to identify further trials. Proceedings from the British
Vascular Surgical Society (Vascular Society abstract books from
1995 to 2011) and the European Vascular Surgical Society (ESVS)
abstract books (from 2001 to 2011) were examined for relevant
trials.
Data collection and analysis
Selection of studies
For this review, two review authors (GA and CT) selected trials
for inclusion in the review. Disagreements were resolved through
discussion. The section ’Criteria for considering studies for this
review’ details the inclusion criteria used for the selection process.
Data extraction and management
Data were extracted by GA then cross checked by CT. Disagree-
ments were resolved through discussion. The following informa-
tion was extracted for each trial.
• Trial methods: method of randomisation, method of
allocation.
• Participants: country of origin, age, sex distribution,
severity of disease as measured by the ABI and using the
European Consensus definition of critical ischaemia (Consensus
document), inclusion and exclusion criteria.
• Interventions: type of procedure (atherectomy, angioplasty
or bypass).
• Outcomes: primary and secondary outcomes as listed in
Types of outcome measures.
Data were extracted from the published reference papers directly.
No attempt was made to obtain additional unpublished data. All
analyses were based on endpoint data from the individual clinical
trials, which all provided intention-to-treat results. The data were
synthesised by comparing group results. Individual patient data
from different trials were not amalgamated.
Assessment of risk of bias in included studies
Risk of bias of the included studies was assessed by two review au-
thors independently (GA, CT), according to the guidelines given
in the Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1 (Higgins 2011).
The following domains were assessed as ’low risk of bias’, ’unclear
risk of bias’ or ’high risk of bias’:
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting.
These assessments were reported for each individual study in the
Risk of bias in included studies tables.
Measures of treatment effect
Treatment effects for dichotomous quantities weremeasured using
risk ratios (RR) with 95% confidence intervals (CI). For contin-
uous quantities, treatment effects were measured by mean differ-
ence with 95% CI.
Unit of analysis issues
Two of the trials (Shammas 2011; Shammas 2012) included mul-
tiple treated vessels per participant in some cases. This means that
the observations from these trials will not be totally independent,
and therefore should have less emphasis placed on them in the
meta-analysis. However, as most participants (88%) in these trials
had only one treated vessel and very few hadmore than two treated
4Atherectomy for peripheral arterial disease (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
vessels (15%), it is not likely that this will have a large impact on
the results presented below. The data could not be re-examined to
an individual participant level.
For the outcomes mortality, fatal and non-fatal cardiovascular
events, complications, quality of life, and clinical and symptomatic
outcomes the unit of analysis was the individual participant rather
than the treated vessel.
Dealing with missing data
Analysis was performed on a complete case basis and no attempt
was made to contact study authors for further follow-up data. It
was not necessary to contact authors for additional data.
Assessment of heterogeneity
Chi2 tests were used to assess for heterogeneity between trials,
with P values greater than 0.2 being used as an indication of the
possibility of the presence of significant heterogeneity. Since trials
contained low participant numbers the power of this test is likely
to be low if a small P value is used (Higgins 2011).
Assessment of reporting biases
There were insufficient studies identified to create a funnel plot to
assess reporting bias.
Data synthesis
As the devices used for atherectomy were different in the in-
cluded trials, analysis was performed using both Mantel-Haenszel
fixed-effect models and inverse-variance random-effects models
(Dersimonian 1986), and the sensitivity of the analysis to the use
of these two methods was assessed. Review Manager (RevMan)
version 5.1 software (RevMan 2012) was used.
Many participants in the atherectomy arm of the included studies
underwent additional angioplasty. Details of this were not speci-
fied exactly in all studies and these participants were therefore not
analysed separately. The result from atherectomy is still consid-
ered successful even with additional angioplasty, so these partic-
ipants were included in the atherectomy arm for analysis. Only
one trial did not perform routine angioplasty with atherectomy
(Vroegindeweij 1995) and sensitivity analyses were performed to
assess the effect of including this study in the overall meta-analy-
ses.
Subgroup analysis and investigation of heterogeneity
No subgroup analysis was performed as no suitable subgroupswere
presented in the selected studies.
Previously planned subgroup analyses were the presence or ab-
sence of concomitant illness such as diabetes, hypertension, hy-
perlipidaemia, chronic kidney disease, smoking, gender of partic-
ipants, lesion location, length and percentage of stenosis includ-
ing whether any studies classified lesion length and percentage of
stenosis by the Trans-Atlantic Inter-Society Consensus Document
on Management of Peripheral Arterial Disease (TASC II) (TASC
II 2007).
Sensitivity analysis
Sensitivity analysis was performed in two ways. Firstly, each meta-
analysis was performed using both fixed-effect and random-effects
models to assess whether the results were robust to changes in this
modelling assumption. Secondly, meta-analysis was repeated after
excluding the study where adjunctive balloon angioplasty was not
routinely performed (Vroegindeweij 1995).
R E S U L T S
Description of studies
Results of the search
See Figure 1
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Figure 1. Study flow diagram.
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Included studies
Summarised details of the included studies are included in the
Characteristics of included studies table.
Four studies met the selection criteria (Nakamura 1995; Shammas
2011; Shammas 2012; Vroegindeweij 1995). Primary patencies
were reported initially in all studies (Nakamura 1995; Shammas
2011; Shammas 2012; Vroegindeweij 1995). Follow-up was re-
ported at three month intervals in Vroegindeweij 1995 up until
two years. Nakamura 1995 reported patencies at six months fol-
low-up only. Shammas 2011 reported follow-up patencies at 12
months only. Shammas 2012 reported follow-up at three months,
six months and 12 months. A total of 220 participants (118
atherectomy, 102 angioplasty) were treated in these trials. Some
trials treated multiple vessels in each participant, so in total 259
vessels (129 atherectomy, 130 angioplasty) were treated in these
trials. Two trials (Shammas 2011; Shammas 2012) also reported
rates of bailout stenting and amputation. This bailout stenting
was said to be indicated in the presence of severe dissection, per-
foration, > 30% residual stenosis or significant vessel recoil in one
paper (Shammas 2012) but only indicated in the presence of se-
vere dissection or > 30% residual stenosis in the other (Shammas
2011).
Nakamura 1995 compared balloon angioplasty to transluminal
extraction catheter (TEC) atherectomy (Stack 1988) followed by
adjunctive balloon angioplasty in 39 participants with intermit-
tent claudication. TEC atherectomy utilises an over the wire de-
vice with a conical motorised cutting head with triangular blades
which rotate at 700 rpm, together with a proximal suction appara-
tus which removes excised plaque. The assembly is controlled by a
large hand-held controller which incorporates the motor, triggers
to activate the motor and suction, and a sliding advancement con-
trol. There was no difference in primary patency either initially (P
= 0.16) or at six months (P = 0.16). No medication protocol was
specified.
Vroegindeweij 1995 compared balloon angioplasty to Simpson
atherectomy (Simpson 1988) in 73 participants with intermittent
claudication. The Simpson atherectomy device consists of cylin-
drical housing with a longitudinal opening down one side and a
balloon on the other side. The device is passed over a guide wire to
the region of stenosis and then the balloon is inflated in order to
both fix the device in place and press the longitudinal opening up
against the wall of the vessel. A rotating cutting blade (2000 rpm)
is then advanced through the cylinder so that any part of the vessel
wall projecting through the longitudinal window will be cut away.
These pieces are pushed into a distal collecting chamber, which
can hold enough for between four and eight passes of the blade.
The balloon is then deflated and the device either repositioned for
further passes or removed, and the collecting chamber emptied.
There was no difference in primary patency between groups at any
time point (log rank P = 0.07). The day before the procedure, all
participants were commenced on low dose aspirin therapy.
Shammas 2011 compared balloon angioplasty to Silverhawk
atherectomy (Zeller 2004) followed by adjunctive balloon angio-
plasty in 58 participants with claudication, rest pain or minor
tissue loss. The Silverhawk atherectomy device is similar to the
Simpson device, described above, except that instead of using a
balloon to push the cutting window against the wall of the vessel
the cylindrical housing is hinged in the region of the window, with
the device flexing away from the window causing the tip and tail of
the device to press up against one side of the vessel wall while the
window is pressed up against the other side. The remainder of the
procedure is similar. There was no difference in primary patency
either initially or at 12months, but bailout stentingwas performed
significantly less often following atherectomy (P = 0.01). One par-
ticipant in the balloon angioplasty arm required an amputation.
In this trial, a distal embolism filter was used in approximately half
of the participants. This filter caught macroembolic material sig-
nificantly more frequently following atherectomy than following
balloon angioplasty (P = 0.001). If participants were not already
established on dual anti-platelet therapy (aspirin and clopidogrel),
they were given loading doses of aspirin and clopidogrel immedi-
ately prior to the procedure. Participants on established therapy
continued on their regular doses.
The final included trial (Shammas 2012) compared balloon an-
gioplasty to Diamondback atherectomy (Heuser 2008) followed
by adjunctive balloon angioplasty in 50 participants with rest pain
or tissue loss and stenosed, calcified vessels. Rather than cutting
plaque away from the vessel wall, the Diamondback atherectomy
device incorporates an eccentrically mounted abrasive crown on a
catheter that rotates at high speed (100,000 rpm) causing plaque
to be filed rather than cut away. As a result, individual pieces of
plaque are likely to be extremely small, so no system for removing
the resulting debris is used. There was no difference in primary
patency at any time point (log rank test P = 0.14) or rates of bailout
stenting (P = 0.44). There were no device or procedure related
above-knee amputations in either group. Unexpectedly, 6/25 par-
ticipants in the balloon angioplasty had died by the 12 month fol-
low-up point, though no good explanation of this could be found
by the trialists. No participants in the atherectomy arm died. No
medication protocol was specified.
Excluded studies
See Characteristics of excluded studies
Four studies were excluded. In Gabrielli 2012 and Gisbertz 2009
remote endarterectomy was performed rather then rotational
atherectomy. NCT01579123 was excluded as a laser atherectomy
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device was used as opposed to the mechanical cutting devices in-
cluded in this review. The results were therefore not directly com-
parable. In Brodmann 2013 the patients had a first in-stent reob-
struction.
Ongoing studies
See Characteristics of ongoing studies
Two studies were ongoing (NCT00986752; NCT01366482),
comparing drug coated balloon angioplasty with atherectomy.
Risk of bias in included studies
The summarised data are included in the Characteristics of
included studies table and Figure 2; Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Nakamura 1995 used a random number table but it was unclear
whether confirmation of suitability of participants in terms of in-
clusion and exclusion criteria were assessed before randomisation.
Shammas 2011 used sealed envelopes for randomisation and stated
that “randomisation was done after crossing total occlusions”, im-
plying that allocation concealment was unclear. Shammas 2012
and Vroegindeweij 1995 both used sealed envelopes for randomi-
sation and allocated participants only after the inclusion and ex-
clusion criteria were evaluated, implying that allocation conceal-
ment was acceptable.
Blinding
Blinding operators for procedure type is not possible in trials of this
nature. Blinding for post-procedure follow-up is possible but does
not appear to have been performed in any of the four trials. There
was, therefore, significant risk of both performance and detection
bias in all four trials.
Incomplete outcome data
Outcome data at six and 12 months follow-up were incomplete
in three of the four studies (Shammas 2011; Shammas 2012;
Vroegindeweij 1995) as significant numbers of the initial study
population were not followed up to later time points. There was,
therefore, significant concern about the presence of attrition bias
but patency rates were reported for those participants who were
followed up for the appropriate periods of time in all four studies.
Selective reporting
Primary patencies were fully reported in all studies but some stud-
ies failed to completely report all secondary outcomes. Nakamura
1995 reported initial and six month patencies, but only reported
ABIs for participants whose vessels remained patent. Shammas
2011 also failed to completely report follow-up ABIs and did
not fully report major adverse events. The remaining two stud-
ies (Shammas 2012; Vroegindeweij 1995) reported all outcomes
fully.
Other potential sources of bias
No further sources of bias were identified.
Effects of interventions
All included studies compared atherectomy versus balloon angio-
plasty. Three studies compared atherectomy plus balloon angio-
plasty with balloon angioplasty (Nakamura 1995; Shammas 2011;
Shammas 2012) and one study compared atherectomy with an-
gioplasty (Vroegindeweij 1995).
Eachmeta-analysis was performed using both fixed-effect and ran-
dom-effects models to assess whether the results were robust to
changes in this modelling assumption. In no case did this change
a significant result to a non-significant result, or vice versa. The
values presented below are those obtained using fixed-effect mod-
els.
Meta-analyses were also repeated after excluding the study where
adjunctive balloon angioplasty was not routinely performed
(Vroegindeweij 1995). Again, there was no change in the signifi-
cance of the results.
Primary outcomes
Primary vessel patency
All four included trials reported initial procedural success rates.
None found a between-treatment difference and this was reflected
in the meta-analysis, which also found no significant difference
between interventions (Mantel-Haenszel RR 0.92, 95% CI 0.44
to 1.91, P = 0.82; Figure 4). Three of the studies reported pri-
mary patency at six months (Nakamura 1995; Shammas 2012;
Vroegindeweij 1995), again without finding significant between-
treatment differences.Meta-analysis also failed to find a significant
between-procedure difference (Mantel-Haenszel RR 0.92, 95%
CI 0.51 to 1.66, P = 0.79; Figure 5). Three of the studies reported
primary patency at 12 months (Shammas 2011; Shammas 2012;
Vroegindeweij 1995) but all found no statistically significant dif-
ference between interventions, which was again reflected in the
meta-analysis (Mantel-Haenszel RR 1.17, 95% CI 0.72 to 1.90,
P = 0.53; Figure 6). In all of these cases heterogeneity was low, so
fixed-effect models were used and presented.
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Figure 4. Forest plot of comparison: 1 Balloon angioplasty versus atherectomy, outcome: 1.1 Initial
technical failure rates.
Figure 5. Forest plot of comparison: 1 Balloon angioplasty versus atherectomy, outcome: 1.2 6 month
vessel occlusion rates.
Figure 6. Forest plot of comparison: 1 Balloon angioplasty versus atherectomy, outcome: 1.3 12 month
vessel occlusion rates.
All-cause mortality
Two studies (Shammas 2011; Shammas 2012) reported mortality
rates at one year. In one of the trials (Shammas 2012) there were
an unexpectedly high number of deaths in the balloon angioplasty
arm (6/25 participants), with no deaths in the atherectomy arm,
though no good explanation of this could be found by the trialists.
In the other trial, there were 4/29 deaths in the balloon angioplasty
arm and 2/29 deaths in the atherectomy arm. Meta-analysis of
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this endpoint showed that this effect reached significance (Mantel-
Haenszel RR 0.24, 95% CI 0.06 to 0.91, P = 0.04; Figure 7).
Figure 7. Forest plot of comparison: 1 Balloon angioplasty versus atherectomy, outcome: 1.6 Mortality.
Fatal and non-fatal cardiovascular events
No fatal or non-fatal cardiovascular events were reported in any of
the included studies. Shammas 2011 declared embolic stroke and
myocardial infarction to be secondary outcomes, but none were
seen in either the treatment or control arm of the study.
Secondary outcomes
Immediate procedural and angiographic outcomes
Two studies (Shammas 2011; Shammas 2012) reported rates of
bailout stenting with fairly similar indications (presence of severe
dissection or > 30% residual stenosis in both studies, also perfo-
ration or significant vessel recoil in one of the studies (Shammas
2012)). One of the studies (Shammas 2012) showed a trend to-
wards a greater need for bailout stenting after angioplasty, while
the other (Shammas 2011) showed a dramatic reduction in the
need for stenting with atherectomy. Meta-analysis confirmed this
result (Mantel-Haenszel RR 0.45, 95% CI 0.24 to 0.84, P = 0.01;
Figure 8). Tests of heterogeneity again did not suggest significant
between-study differences.
Figure 8. Forest plot of comparison: 1 Balloon angioplasty versus atherectomy, outcome: 1.4 Bailout
stenting.
Two studies (Shammas 2011; Shammas 2012) reported balloon
inflation pressures during angioplasty (in both studies balloon an-
gioplasty was routinely performed following atherectomy). Both
studies reported significantly lower inflation pressures following
atherectomy than during stand-alone balloon angioplasty. Meta-
analysis confirmed this finding (mean difference -2.73 mmHg,
95% CI -3.48 to -1.98, P < 0.00001; Figure 9).
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Figure 9. Forest plot of comparison: 1 Balloon angioplasty versus atherectomy, outcome: 1.7 Balloon
inflation pressure.
Target vessel revascularisation rates
Shammas 2011 reported target vessel revascularisation rates at one
year, reporting 6/28 vessels in the angioplasty arm and 3/27 in the
atherectomy arm. This difference was not statistically significant.
None of the other studies reported this outcome separately.
Complication rates
Shammas 2012 reported that one participant in the atherectomy
arm and six participants in the angioplasty arm experienced vessel
dissection. Five of these were treated by stent placement, and two
(both in the angioplasty arm) were treated with dilatation. One
participant in the atherectomy arm received a stent for slow flow
and one participant in the angioplasty arm received a stent for
vessel recoil. One participant in the angioplasty arm experienced
vessel perforation, treated by balloon dilatation, and one partici-
pant in the angioplasty arm experienced distal embolisation.
Shammas 2011 reported that one participant in the atherectomy
arm who was not treated with a distal embolisation filter had
clinically significant distal embolisation requiring mechanical and
pharmacological therapy. Seventeen participants in the atherec-
tomy arm were treated with a distal embolisation filter, of whom
11 had macroembolisation with debris larger than 2 mm captured
in the filter. None of the 10 participants in the angioplasty group
who were treated with a filter had significant debris caught in the
filter. No participants treated with a filter had clinically significant
embolisation distal to the filter and all filters were removed with-
out further complications.
Morbidity assessment
Two studies (Shammas 2011; Shammas 2012) reported rates of
above-knee amputation at one year. There was only one event
in either of the trials (in the angioplasty arm of Shammas 2011)
so, given the low event rate and small numbers, it is difficult to
draw any meaningful conclusions about this adverse event (Man-
tel-Haenszel RR 0.33, 95% CI 0.01 to 7.80).
Quality of life outcomes
The included studies did not report on quality of life outcomes.
Clinical and symptomatic outcomes
The included studies did not report on clinical and symptomatic
outcomes such as walking distance or symptom relief.
Other outcomes
Vroegindeweij 1995 performed a post hoc analysis to assess the
effect of lesion length on patency. Using life-table analysis, they
showed that atherectomy was equivalent to balloon angioplasty
for short lesions (< 2 cm), but for longer lesions long-term patency
was significantly better following balloon angioplasty (P = 0.007).
Shammas 2011 also reported 30 day and 12 month ABI and
Rutherford class, high sensitivity C-reactive protein (CRP) and
post-procedural Thrombolysis in Myocardial Infarction (TIMI)
flow grade, reporting no significant difference between any of these
outcomes in the two treatment arms. Shammas 2012 reported an
aggregate major adverse events endpoint, which included ampu-
tation, all-cause mortality and need for target lesion revascularisa-
tion. Participants in the balloon angioplasty arm were significantly
more likely to suffer one of these major adverse events (P = 0.006),
although this was affected by the unexpectedly high number of
deaths in this trial.
D I S C U S S I O N
Summary of main results
The main finding from the four RCTs identified was that there
was no primary patency benefit to atherectomy over balloon an-
gioplasty. There was a statistically significant difference in all-cause
mortality, likely to be caused by an unexpectedly high mortality
in the angioplasty arm of one of the two trials reporting mortality.
Cardiovascular events were not reported in any of the trials. There
was a reduction in the need for bailout stenting associated with a
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reduction in the inflation pressure necessary to achieve an optimal
balloon inflation. Complications such as embolisation and vessel
dissection were reported in two trials, indicating more embolisa-
tions in the atherectomy group and more vessel dissections in the
angioplasty group, but the data could not be pooled. No statisti-
cally significant differences were found between the atherectomy
and balloon angioplasty groups for adverse events, such as data on
target vessel revascularisation and above-knee amputation, but the
data were limited. Quality of life and clinical and symptomatic
outcomes such as walking distance or symptom relief were not
reported in the studies. The trials were not adequately powered,
had low participant numbers and poor overall quality relating to
blinding and poor reporting of outcomes resulting in high risks of
bias.
Overall completeness and applicability of
evidence
This represents the only meta-analysis of atherectomy versus any
other therapy for peripheral arterial disease to date.
The indication for intervention was claudication in two studies
(Nakamura 1995; Vroegindeweij 1995); claudication, rest pain
or tissue loss in another trial (Shammas 2011); and rest pain or
tissue loss only in the final study (Shammas 2012). Results of
angioplasty and bypass surgery are known to vary between these
patient groups (TASC II 2007) and therefore may bias the results
between studies. The severity of claudication was impossible to
assess in some included studies, which may mean that the results
are for patient groups treated conservatively in many UK centres
(Frans 2012), so the results should be interpreted with a degree
of caution. Unfortunately we were not able to separate results by
symptoms (claudication or critical ischaemia) because of the way
study results were reported. In addition, the majority of included
studies did not report on all of the pre-specified outcomes of this
review, so the results of this review are based in most cases on
results from only one or two studies.
Quality of the evidence
All four included studies were of poor quality. In addition, there
were differences in patient groups, trial protocols and target vessels.
Only one trial (Shammas 2011) showed power calculations to as-
sess the required number of participants. Overall study numbers
were low and meta-analysis of such small participant number ran-
domised trials can be unreliable (Rerkasem 2010). As a result, the
lack of difference in primary patency that was found could easily
be type II error.Medication protocols were not stated in two of the
trials (Nakamura 1995; Shammas 2012). This may be important
as it is known that antiplatelet, cilostazol, and heparin use are all
associated with lower restenosis rates after angioplasty (Robertson
2012). Important clinical endpoints such as secondary patency,
limb survival, and complication rates between techniques were not
included in all trials to analyse in detail.
Several factors may contribute to heterogeneity between stud-
ies even though from the forest plots this was non-significant.
One included study compared atherectomy alone with balloon
angioplasty (Vroegindeweij 1995), whereas the other three tri-
als (Nakamura 1995; Shammas 2011; Shammas 2012) compared
atherectomy plus adjunctive balloon angioplasty with balloon an-
gioplasty alone. Superficially this creates concern about hetero-
geneity, however three participants in the atherectomy arm of
Vroegindeweij 1995 crossed over and had subsequent balloon an-
gioplasty after failure of atherectomy alone. Additionally, balloon
pressures reported in two of the other studies following atherec-
tomy were usually very low, so it is likely that these interventions
were more similar than they might appear. Sensitivity analysis ex-
cluding the Vroegindeweij 1995 study did not change the statis-
tical significance of the results.
One concern with atherectomy devices is the risk of distal emboli-
sation, since the devices physically cut or grind plaques (Briguori
2003). In one of the included studies (Shammas 2011) this was
found to be a particular issue and a distal embolic filter was de-
ployed in 17/29 of participants, which caught macroembolic de-
bris (defined as debris greater than 2mm in the longest axis) in 11/
17 cases. The filter was deployed in 10/29 of the participants in
the balloon angioplasty arm but did not catch macroemboli in any
cases. In addition, one participant in the atherectomy armwhowas
treated without a filter had a clinically significant distal embolic
event. In contrast, only one other case of distal embolisation was
reported in the other three trials (Shammas 2012: one participant
in the balloon angioplasty arm had a clinically significant embolic
event). As no other studies reported rates of distal embolic filter
deployment or macroembolisation, this could not be analysed but
remains a specific concern.
Mortality is commonly reported in trials of lower limb revasculari-
sation, which is why it was considered a primary outcomemeasure.
However, the mortality from angioplasty is much lower than is
primary patency or limb loss rates (Laird 2010; Schillinger 2006),
so trials would not be expected to show a difference if powered
to detect primary patency. The results presented may be a conse-
quence of random error due to small sample sizes. There was a sta-
tistically significant difference in all-cause mortality that was likely
to be caused by an unexpectedly high mortality in the angioplasty
arm of one of the two trials reporting all-cause mortality.
The poor overall quality of the included trials is a major limitation
of this review. A lack of power calculations, protocol uniformity
and heterogeneity between trials means that the conclusions that
can be drawn from the analyses are limited. However, what is clear
from this review is that there is currently no evidence to support the
use of atherectomy as a treatment for peripheral vascular disease.
Potential biases in the review process
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The review process identified only four small trials, so it is difficult
to assess the impact of reporting bias. Given the general trend to-
wards the publication of positive findings, especially in the context
of new technologies, it is possible that the analysis actually over-
estimates the benefits of atherectomy over the more established
balloon angioplasty.
Some trials (Shammas 2011; Shammas 2012) treated more than
one vessel per participant or limb. Failure of patency of any of
the treated vessels increases the chances that other treated vessels
will cease to be patent, so these observations will be correlated. It
is possible, therefore, that the outcomes of these trials are given
greater weight in the meta-analysis than is appropriate in the anal-
ysis of six month and 12 month patency. As both the angioplasty
and atherectomy arms of these trials included multiple vessels per
participant it is unlikely that the magnitude of the observed effect
has been affected significantly, though our degree of confidence in
this effect may be overstated.
Agreements and disagreements with other
studies or reviews
While there were no previous meta-analyses of atherectomy for
peripheral arterial disease, atherectomy has been more thoroughly
investigated in the coronary arteries. A large meta-analysis com-
paring multiple randomised trials of atherectomy or other plaque
debulking procedures with balloon angioplasty in percutaneous
coronary intervention showed no benefit for atherectomy (Bittl
2004). The studies in the analysis by Bittl 2004 were almost all per-
formed in the 1990s, when coronary stenting was still evolving. A
meta-analysis of trials comparing coronary stenting with atherec-
tomy followed by stenting has shown that debulking procedures
may indeed confer long-term benefit (Niccoli 2006). However,
the majority of trials that were analysed were small case-control
studies rather than RCTs, and the one large RCT that was analysed
failed to show benefit (Stankovic 2004).
Balloon angioplasty for peripheral vascular disease is widely prac-
tised, has a clear evidence base and is constantly evolving, with
the use of covered stents and drug eluting devices, to improve
results (Schillinger 2009; TASC II 2007). As the technique has
evolved so has the evidence base for its place compared to exer-
cise therapy and bypass surgery (Bradbury 2010; Mazari 2012).
Based on the results of this review the routine use of atherectomy,
against balloon angioplasty, cannot be recommended. Performing
a properly powered randomised trial of atherectomy versus bal-
loon angioplasty to look at primary patency or limb survival may
be inappropriate considering the lack of difference in this analy-
sis, increased technical difficulty, complication rates and the exist-
ing ’gold standard’ practice of angioplasty. The exception to this
may be in patients with TASC C or D lesions who are not fit for
bypass surgery. Atherectomy may offer benefit over the relatively
poor results of long segment subintimal angioplasty in this patient
group, although results from cohort studies imply that subintimal
angioplasty may be superior in this setting (Indes 2010).
Stenting in peripheral arterial disease has been the focus of signif-
icant recent attention. Several randomised trials comparing stent-
ing to angioplasty alone have been reported recently, the majority
favouring stenting (Dake 2011; Krankenberg 2007; Laird 2010;
Schillinger 2006). All of these trials contained significant cross
over, with rates of bailout stenting in the control arm ranging
from 32% to 50%. In this context, it was unsurprising to find
that the rate of bailout stenting in the angioplasty arm of one of
the more recent studies was 50%, and 22% in the atherectomy
arm (Shammas 2011). More surprising was the unexpectedly low
rate of bailout stenting in the angioplasty and stenting arms of the
most recent included study (14% and 7% respectively) (Shammas
2012) despite the more permissive indications used in this trial.
This may suggest treatment of more minor lesions in the latter
study, a possibility which is difficult to verify as summary TASC
lesion categories were not published.
In conclusion, there were no high quality trials comparing atherec-
tomy with any other established intervention for peripheral vas-
cular disease. Meta-analysis of four low quality trials comparing
atherectomywith balloon angioplasty showed no difference in pri-
mary patency rates at any time interval. Given the widespread
practice, clear evidence base, and established gold standard guide-
lines for balloon angioplasty, atherectomy has no place in the
routine treatment of people with peripheral arterial disease who
are amenable to standard angioplasty. There was no evidence for
atherectomy versus bypass surgery, but the use of atherectomy for
more severe (TASC C or D) disease when bypass surgery is con-
traindicated or inappropriate should be limited to clinical trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has identified poor quality evidence to support
atherectomy as an alternative to balloon angioplasty in maintain-
ing primary patency at any time interval. With the exception of
mortality, there was no evidence for superiority of atherectomy
over angioplasty for any outcome, and distal embolisation was not
reported in all trials of atherectomy.
The findings of this review are not sufficient to challenge the cur-
rent widespread practice, clear evidence base, and established gold
standard guidelines for balloon angioplasty in the routine treat-
ment of people with peripheral arterial disease who are amenable
to standard angioplasty.
Implications for research
Current evidence in this area is poor. Larger and better designed
trials in selected subgroups of participants are needed.
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Future trials should be as follows.
1. Better powered to detect smaller differences. Existing
evidence is sufficient to say that there is no large overwhelming
benefit of atherectomy but a more moderate benefit could still
exist.
2. Have participants separated into claudicant and critically
ischaemic groups.
3. More rigorous with follow-up. Existing studies rate poorly
in terms of outcome assessment blinding and subject attrition. It
is important that future studies have both longer follow-up and
blinded outcome assessment. As the procedures are often
performed by interventional radiologists but followed up by
vascular surgeons, this latter point should not be too difficult to
achieve.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Nakamura 1995
Methods Randomisation: random number table
Participants Country: United States of America
No. of participants: 39:
- 2.7 mm TEC atherectomy plus balloon angioplasty: 13
- 4.0 mm TEC atherectomy plus balloon angioplasty: 13
- balloon angioplasty: 13.
Age (mean (years) ± SD):
- 2.7 mm TEC: 64 ± 6
- 4.0 mm TEC: 70 ± 6
- balloon angioplasty: 61 ± 4.1
Inclusion criteria: occluded SFA with 1 - 2 block claudication
Exclusion criteria: those with previous femoro-popliteal graft or “insufficient run-off
vessels”
Interventions Balloon angioplasty versus 2.7 mm TEC atherectomy plus balloon angioplasty versus 4.
0 mm TEC atherectomy plus balloon angioplasty
Outcomes Initial and 6 month vessel patency
Pre-procedure and 6 month ankle-brachial pressure index (6 month ABI only reported
for participants with primary patency at 6 months)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomnumber table used for randomisation
Allocation concealment (selection bias) Unclear risk Not specifically stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither participants nor personnel were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mention of blinding of outcome assess-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete data available to 6 months
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Nakamura 1995 (Continued)
Selective reporting (reporting bias) Unclear risk Initial and 6 month patencies reported. An-
kle-brachial pressure index only reported for
subjects whose vessels remained patent at 6
months
Other bias Low risk No other potential source identified
Shammas 2011
Methods Randomisation: sealed envelopes
Participants Country: United States of America
No. of participants: participants: 58; vessels: 84
- Silverhawk atherectomy plus balloon angioplasty: participants: 29; vessels: 36
- balloon angioplasty: participants: 29; vessels: 48
Age (mean (years) ± SD):
- atherectomy: 67.4 ± 9.1
- balloon angioplasty: 70.9 ± 13.9
Inclusion criteria: adults with claudication, rest pain or minor tissue loss
Exclusion criteria: (i) heavily calcified vessels; (ii) total occlusions longer than 10 cm or
any total occlusion with suspicion of subintimal wire recanalisation, (iii) inability to take
aspirin or adenosine diphosphate receptor antagonists, (iv) bleeding disorder or platelet
count less than 100,000/L, (v) creatinine level greater than 2.5mg/dL, (vi) unwillingness
to give consent or return for future follow-up visits, (vii) ongoing active infection, (viii)
decompensated congestive heart failure or acute coronary syndrome, or (ix) a staged
vascular procedure during the same hospital stay or 1 week after the index procedure
Interventions Balloon angioplasty versus Silverhawk atherectomy with adjunctive balloon angioplasty
Outcomes Primary: Target lesion revascularisation at 1 year
Secondary:
(i) The rate of “bailout” stent implantation because of suboptimal acute angiographic
results, defined as a residual stenosis of more than 30% or the presence of type C-F
dissection
(ii) Final acute angiographic results in each arm at the end of the procedure
(iii) Target vessel revascularisation at 1 year
(iv) Major adverse events including major amputation, death, distal embolisation, vascu-
lar complications (arteriovenous fistula, pseudoaneurysm, or perforation), major bleed-
ing (loss of 3U of packed red blood cells with a source of bleeding, or intracranial or
retroperitoneal bleeding), unplanned urgent revascularisation of the treated vessel in the
same hospital stay, myocardial infarction, embolic stroke, and renal failure (i.e., increase
in creatinine clearance by 25% versus pre-procedure baseline)
(v) Change in the ankle-brachial index at 1 month, 6 months, and 1 year after the
procedure versus baseline
Notes
Risk of bias
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Shammas 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes used for randomisation
Allocation concealment (selection bias) Unclear risk Not specifically stated, but appears to have been
acceptable: Authors state “Randomization was per-
formed after total occlusions were crossed”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated, but impractical in trials of this type
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated, probably not done
Incomplete outcome data (attrition bias)
All outcomes
High risk Primary outcome only reported for 51/84 vessels
Selective reporting (reporting bias) High risk Secondary outcomes (iv) and (v) incompletely re-
ported
Other bias Low risk No other potential source identified
Shammas 2012
Methods Randomisation: sealed envelopes
Participants Country: United States of America
No. of participants: participants: 50; vessels: 64
- Diamondback atherectomy plus balloon angioplasty: participants: 25; vessels: 29
- balloon angioplasty: participants: 25; vessels: 35
Age (mean (years) ± SD):
- atherectomy: 70.7 ± 13.4
- balloon angioplasty: 71.8 ± 10.9
Inclusion criteria: adults with rest pain or tissue loss (Rutherford class 4 - 6). Also angio-
graphic stenosis > 50%, fluoroscopically-visible calcium > 25% of the treated segment,
atherectomy wire must cross all lesions with no subintimal wire passage, main target
vessel reference diameter > 1.5 mm, more than one patent distal runoff vessel with brisk
flow for any treated popliteal segment, distal portion of anterior tibial or posterior tibial
target vessel must reconstitute to the ankle or foot and only proximal one third of the
peroneal artery to be treated; distal two thirds must reconstitute
Exclusion criteria: (i) inability to understand study or history of non-compliance with
medical advice, (ii) unwilling or unable to sign informed consent form, (iii) currently
enrolled in another study that may interfere with study endpoints, (iv) unsuccessful
treatment of target leg superficial femoral artery or proximal vessel on procedure day, (v)
pregnant or planning to become pregnant within study period, (vi) known sensitivity
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Shammas 2012 (Continued)
to contrast media that cannot be adequately premedicated, (vii) chronic renal failure/
creatinine level > 2.0 mg/dL unless on chronic dialysis, (viii) one or more of the popliteal
or below-knee lesions to be treated are within a stent, (ix) known allergy to heparin,
aspirin, or clopidogrel, (x) history of bleeding disorders or platelet count < 80,000 cells/
mL, (xi) ongoing cardiac problems thatwould interferewith study procedures, (xii) stroke
or transient ischaemic attack within 4 weeks prior to procedure, (xiii) anticipated lifespan
< 1 year, (xiv) known or suspected active systemic infection, (xv) thrombus present
or suspected in the target vessel, (xvi) concomitant thrombectomy/other atherectomy
device treatment in target vessel, (xvii) investigator’s medical judgment excludes subject
from the study
Interventions Balloon angioplasty versus Diamondback atherectomy with adjunctive balloon angio-
plasty
Outcomes Primary: ability to achieve adequate lumen diameter, defined as < 30% residual stenosis
with no bailout stenting or dissection
Secondary: rate of bailout stenting; limb salvage at 30 days, 6 months and 12 months;
target lesion and vessel revascularisation (TLR/TVR) at 6 and 12 months; and major
adverse events (a composite of above-knee amputation, mortality from all causes, and
TLR/TVR)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes provided to all centres for randomi-
sation
Allocation concealment (selection bias) Low risk Randomisation performed only after inclusion and
exclusion criteria assessed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated, but impractical in trials of this type
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated, probably not done
Incomplete outcome data (attrition bias)
All outcomes
High risk Secondary outcomes reported for only 33/50 par-
ticipants
Selective reporting (reporting bias) Low risk All outcomes reported, though significant attrition
present
Other bias Low risk No other potential source identified
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Vroegindeweij 1995
Methods Randomisation: Numbered envelopes opened sequentially
Participants Country: Netherlands
No. of participants: 73
Simpson atherectomy: 38
Balloon angioplasty: 35
Age (mean (years) range):
Atherectomy: 64 (range 49 - 77)
Balloon angioplasty: 64 (range 46 - 80)
Inclusion criteria: intermittent claudication of at least 3months duration and obstructive
lesions of the femoropopliteal arteries with a maximum length of 5 cm or complete
occlusions shorter than 2 cm
Exclusion criteria: any previous ipsilateral femoropopliteal endovascular or operative
intervention; participant unable to comply with the frequent follow-up visits required
by the protocol
Interventions Balloon angioplasty versus Simpson atherectomy
Outcomes (i) Primary patency during follow-up
(ii) Restenosis as determined by duplex ultrasound
Notes Four participants crossed over to the other treatment group: three participants had an-
gioplasty following atherectomy, one participant had atherectomy in addition to angio-
plasty. Results were presented in an intention-to-treat format
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Numbered envelopes opened sequentially
Allocation concealment (selection bias) Low risk Randomisation not performed until after
inclusion and exclusion criteria evaluated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated, but impractical in trials of this
type
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated, probably not done
Incomplete outcome data (attrition bias)
All outcomes
High risk Three participants in the balloon angio-
plasty group were not followed up to six
months. One participant in the atherec-
tomy group and 10 in the balloon angio-
plasty group were not followed up to one
year
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Vroegindeweij 1995 (Continued)
Selective reporting (reporting bias) Low risk Primary patency reported fully in life-table
format; restenosis presented graphically
Other bias Low risk No other potential source identified
ABI: ankle brachial index
SD: standard deviation
SFA: superficial femoral artery
TEC: transluminal extraction catheter
TLR: target lesion revascularisation
TVR: target vessel revascularisation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brodmann 2013 Patients with a first in-stent reobstruction
Gabrielli 2012 Remote endarterectomy rather than atherectomy
Gisbertz 2009 Remote endarterectomy rather than atherectomy
NCT01579123 Laser atherectomy versus angioplasty
Characteristics of ongoing studies [ordered by study ID]
NCT00986752
Trial name or title Efficacy study of stenting, paclitaxel eluting balloon or atherectomy to treat peripheral artery disease (ISAR-
STATH)
Methods RCT
Allocation: randomised
Intervention model: parallel assignment
Masking: single blind (outcomes assessor)
Participants Peripheral vascular disease
Male or female 18 years and older
Inclusion criteria:
• symptomatic ≥ 70% stenosis of the SFA (Rutherford stage 2 - 6)
• written informed consent
Exclusion criteria:
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NCT00986752 (Continued)
• acute ischaemia and/or acute thrombosis of the SFA
• untreated ipsilateral iliac artery stenosis > 70%
• previous stenting of the SFA
• popliteal stenosis > 70%
• severe renal insufficiency
Interventions Arm 1: stenting (Smart stent) (Due to randomisation one nitinol stent will be implanted after dilation with
a conventional balloon)
Arm 2: stenting after paclitaxel eluting balloon (Smart stent, Invatec) (Due to randomisation one nitinol stent
will be implanted after dilation with a paclitaxel eluting balloon)
Arm 3: atherectomy (SilverHawk device)
Outcomes Primary outcome measures:
• percentage diameter stenosis (time frame: 6 months) (designated as safety issue: no)
Secondary outcome measures:
• all-cause mortality (time frame: 6 and 24 months) (designated as safety issue: yes)
• major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation
or revascularisation (PTA or bypass surgery) (time frame: 6 months) (designated as safety issue: yes)
• time to onset of any of MAPE (time frame: 3 - 24 months) (designated as safety issue: yes)
• binary restenosis rate (time frame: 6 months) (designated as safety issue: no)
• percentage diameter stenosis in duplex ultrasound (time frame: 6 and 24 months) (designated as safety
issue: no)
• change from baseline in functional status and health related quality of life (Walking Impairment
Questionaire) (time frame: 3 and 6 months)
Starting date July 2009
Contact information Klaus Tiroch
Notes
NCT01366482
Trial name or title Atherectomy followed by a drug coated balloon to treat peripheral arterial disease (DEFINITIVE AR)
Methods RCT
Allocation: randomised
Intervention model: parallel assignment
Masking: double blind (subject, outcomes assessor)
Participants Inclusion criteria:
• Rutherford clinical category 2 - 4
• at least 18 years of age
• is able and willing to provide written informed consent prior to study specific procedures
Exclusion criteria:
• has a life expectancy of less than 24 months
• is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing
• has one or more of the contraindications listed in the SilverHawk/TurboHawk or Cotavance
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NCT01366482 (Continued)
instructions for use
Interventions Arm 1: Cotavance drug-eluting balloon (treatment with a paclitaxel coated angioplasty balloon (without
preceding plaque excision)
Arm 2: TurboHawk/SilverHawk device followed by a Cotavance drug eluting balloon (plaque excision fol-
lowed by treatment with a paclitaxel coated angioplasty balloon)
Arm 3: TurboHawk/SilverHawk device followed by a Cotavance drug eluting balloon (non-randomised arm;
subjects with severe calcification will be assigned to a non-randomised arm and treated with plaque excision
followed by a drug eluting balloon)
Outcomes Primary outcome measures:
• target lesion percent stenosis (time frame: 1 year) (designated as safety issue: no)
Starting date July 2011
Contact information Professor Thomas Zeller
Notes
PTA: percutaneous transluminal angioplasty
RCT: randomised controlled trial
SFA: superficial femoral artery
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D A T A A N D A N A L Y S E S
Comparison 1. Balloon angioplasty versus atherectomy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Initial technical failure rates 4 259 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.44, 1.91]
2 6 month vessel occlusion rates 3 143 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.51, 1.66]
3 12 month vessel occlusion rates 3 143 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.72, 1.90]
4 Mortality 2 108 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.06, 0.91]
5 Amputation 2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.80]
6 Bailout stenting 2 148 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.24, 0.84]
7 Balloon inflation pressure 2 148 Mean Difference (IV, Fixed, 95% CI) -2.73 [-3.48, -1.98]
Analysis 1.1. Comparison 1 Balloon angioplasty versus atherectomy, Outcome 1 Initial technical failure
rates.
Review: Atherectomy for peripheral arterial disease
Comparison: 1 Balloon angioplasty versus atherectomy
Outcome: 1 Initial technical failure rates
Study or subgroup Atherectomy Angioplasty Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nakamura 1995 5/26 3/13 30.6 % 0.83 [ 0.23, 2.96 ]
Shammas 2011 1/36 0/48 3.3 % 3.97 [ 0.17, 94.78 ]
Shammas 2012 2/29 6/34 42.2 % 0.39 [ 0.09, 1.79 ]
Vroegindeweij 1995 5/38 3/35 23.9 % 1.54 [ 0.40, 5.96 ]
Total (95% CI) 129 130 100.0 % 0.92 [ 0.44, 1.91 ]
Total events: 13 (Atherectomy), 12 (Angioplasty)
Heterogeneity: Chi2 = 2.60, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours atherectomy Favours angioplasty
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Analysis 1.2. Comparison 1 Balloon angioplasty versus atherectomy, Outcome 2 6 month vessel occlusion
rates.
Review: Atherectomy for peripheral arterial disease
Comparison: 1 Balloon angioplasty versus atherectomy
Outcome: 2 6 month vessel occlusion rates
Study or subgroup Atherectomy Angioplasty Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nakamura 1995 12/21 5/10 42.7 % 1.14 [ 0.56, 2.35 ]
Shammas 2012 0/22 3/20 23.1 % 0.13 [ 0.01, 2.38 ]
Vroegindeweij 1995 7/38 5/32 34.2 % 1.18 [ 0.41, 3.36 ]
Total (95% CI) 81 62 100.0 % 0.92 [ 0.51, 1.66 ]
Total events: 19 (Atherectomy), 13 (Angioplasty)
Heterogeneity: Chi2 = 2.30, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours atherectomy Favours angioplasty
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Analysis 1.3. Comparison 1 Balloon angioplasty versus atherectomy, Outcome 3 12 month vessel occlusion
rates.
Review: Atherectomy for peripheral arterial disease
Comparison: 1 Balloon angioplasty versus atherectomy
Outcome: 3 12 month vessel occlusion rates
Study or subgroup Atherectomy Angioplasty Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shammas 2011 3/27 4/24 22.1 % 0.67 [ 0.17, 2.68 ]
Shammas 2012 1/15 3/15 15.6 % 0.33 [ 0.04, 2.85 ]
Vroegindeweij 1995 23/37 10/25 62.3 % 1.55 [ 0.90, 2.67 ]
Total (95% CI) 79 64 100.0 % 1.17 [ 0.72, 1.90 ]
Total events: 27 (Atherectomy), 17 (Angioplasty)
Heterogeneity: Chi2 = 3.00, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours atherectomy Favours angioplasty
Analysis 1.4. Comparison 1 Balloon angioplasty versus atherectomy, Outcome 4 Mortality.
Review: Atherectomy for peripheral arterial disease
Comparison: 1 Balloon angioplasty versus atherectomy
Outcome: 4 Mortality
Study or subgroup Atherectomy Angioplasty Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shammas 2011 2/29 4/29 38.1 % 0.50 [ 0.10, 2.52 ]
Shammas 2012 0/25 6/25 61.9 % 0.08 [ 0.00, 1.30 ]
Total (95% CI) 54 54 100.0 % 0.24 [ 0.06, 0.91 ]
Total events: 2 (Atherectomy), 10 (Angioplasty)
Heterogeneity: Chi2 = 1.42, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours atherectomy Favours angioplasty
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Analysis 1.5. Comparison 1 Balloon angioplasty versus atherectomy, Outcome 5 Amputation.
Review: Atherectomy for peripheral arterial disease
Comparison: 1 Balloon angioplasty versus atherectomy
Outcome: 5 Amputation
Study or subgroup Atherectomy Angioplasty Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shammas 2011 0/24 1/24 100.0 % 0.33 [ 0.01, 7.80 ]
Shammas 2012 0/14 0/14 Not estimable
Total (95% CI) 38 38 100.0 % 0.33 [ 0.01, 7.80 ]
Total events: 0 (Atherectomy), 1 (Angioplasty)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours atherectomy Favours angioplasty
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Analysis 1.6. Comparison 1 Balloon angioplasty versus atherectomy, Outcome 6 Bailout stenting.
Review: Atherectomy for peripheral arterial disease
Comparison: 1 Balloon angioplasty versus atherectomy
Outcome: 6 Bailout stenting
Study or subgroup Atherectomy Angioplasty Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shammas 2011 8/36 24/48 81.9 % 0.44 [ 0.23, 0.87 ]
Shammas 2012 2/29 5/35 18.1 % 0.48 [ 0.10, 2.31 ]
Total (95% CI) 65 83 100.0 % 0.45 [ 0.24, 0.84 ]
Total events: 10 (Atherectomy), 29 (Angioplasty)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours atherectomy Favours angioplasty
Analysis 1.7. Comparison 1 Balloon angioplasty versus atherectomy, Outcome 7 Balloon inflation pressure.
Review: Atherectomy for peripheral arterial disease
Comparison: 1 Balloon angioplasty versus atherectomy
Outcome: 7 Balloon inflation pressure
Study or subgroup Atherectomy Angioplasty
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shammas 2011 36 7.9 (1.7) 48 10.5 (2.1) 85.6 % -2.60 [ -3.41, -1.79 ]
Shammas 2012 29 5.9 (4.2) 35 9.4 (3.8) 14.4 % -3.50 [ -5.48, -1.52 ]
Total (95% CI) 65 83 100.0 % -2.73 [ -3.48, -1.98 ]
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 7.11 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours atherectomy Favours angioplasty
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Arteriosclerosis] this term only 894
#2 MeSH descriptor: [Arteriolosclerosis] this term only 0
#3 MeSH descriptor: [Arteriosclerosis Obliterans] this term only 72
#4 MeSH descriptor: [Atherosclerosis] this term only 423
#5 MeSH descriptor: [Arterial Occlusive Diseases] this term only 775
#6 MeSH descriptor: [Intermittent Claudication] this term only 729
#7 MeSH descriptor: [Ischemia] this term only 771
#8 MeSH descriptor: [Peripheral Vascular Diseases] explode all
trees
2202
#9 MeSH descriptor: [Vascular Diseases] this term only 396
#10 MeSH descriptor: [Leg] explode all trees and with qualifiers:
[Blood supply - BS]
1092
#11 MeSH descriptor: [Femoral Artery] explode all trees 739
#12 MeSH descriptor: [Popliteal Artery] explode all trees 263
#13 MeSH descriptor: [Iliac Artery] explode all trees 152
#14 MeSH descriptor: [Tibial Arteries] explode all trees 30
#15 (atherosclero* or arteriosclero* or PVD or PAOD or PAD) 18024
#16 (arter*) near (*occlus* or steno* or obstuct* or lesio* or block*
or obliter*)
5003
#17 (vascular) near (*occlus* or steno* or obstuct* or lesio* or
block* or obliter*)
1437
#18 (vein*) near (*occlus* or steno* or obstuct* or lesio* or block*
or obliter*)
756
#19 (veno*) near (*occlus* or steno* or obstuct* or lesio* or block*
or obliter*)
1012
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(Continued)
#20 (peripher*) near (*occlus* or steno* or obstuct* or lesio* or
block* or obliter*)
1393
#21 peripheral near/3 dis* 3407
#22 arteriopathic 20
#23 (claudic* or hinken*) 1497
#24 (isch* or CLI) 17493
#25 dysvascular* 29
#26 leg near/4 (obstruct* or occlus* or steno* or block* or obliter*) 191
#27 limb near/4 (obstruct* or occlus* or steno* or block* or
obliter*)
244
#28 (lower near/3 extrem*) near/4 (obstruct* or occlus* or steno*
or block* or obliter*)
149
#29 (aort* or iliac or femoral or popliteal or femoro* or fempop*
or crural) near/3 (obstruct* or occlus*)
340
#30 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or
#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28 or #29
41325
#31 MeSH descriptor: [Atherectomy] this term only 25
#32 atherect*:ti,ab,kw (Word variations have been searched) 199
#33 SilverHawk or “Silver Hawk” 7
#34 Jetstream:ti,ab,kw (Word variations have been searched) 1
#35 plaque near/3 excis*:ti,ab,kw (Word variations have been
searched)
7
#36 atheroablation or rotational or orbital:ti,ab,kw (Word varia-
tions have been searched)
648
#37 angle near/3 blade*:ti,ab,kw (Word variations have been
searched)
8
#38 cut near/3 blade*:ti,ab,kw (Word variations have been
searched)
8
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(Continued)
#39 blade near/3 cathet*:ti,ab,kw (Word variations have been
searched)
0
#40 EV3:ti,ab,kw (Word variations have been searched) 11
#41 #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #
39 or #40
824
#42 #30 and #41 in Trials 119
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 3, 2014
Date Event Description
29 October 2008 Amended Converted to new review format.
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Christopher Twine: decided which trials should be included, cross checked data extraction, assessed trial quality, reviewed and edited
review text.
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